Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Respigam for RSV Prevention in Bone Marrow Transplant Recipients
NCT00001903Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 1999
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of respiratory syncytial virus immunoglobulin in respiratory syncytial virus infection (RSV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Incidence of progression to RSV pneumonia at 42 days. Started Apr 1999; status: completed.
02
Drugs
respiratory syncytial virus immunoglobulin
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00001903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001903.